Means for litaize urinary stones and method thereof

 

(57) Abstract:

The invention relates to pharmaceuticals, in particular to the means of supporting litaize urinary stones. The invention consists in that the means for litaize urinary stones based drug xidian additionally contains galangal in a certain ratio xidian : galangal. Also stated its production method by mixing 2%-aqueous solution of califona with 1% solution of galangal in a 1 : 1 ratio. The invention provides improved litaize urinary stones without significant side effects due to the possibility of regulating the pH of urine. 2 N. p. F.-ly, 1 table.

The invention relates to the medical industry, in particular to the pharmaceutical form of the drug, contributing to the dissolution of urinary stones.

All urinary stones are divided into groups: uric acid, urates, oxalates, phosphates, and others. The composition of the stones in most cases, multiphase (Yu, alyayev and other Complex study of urinary stones, inch, T. 47, No. 3, 2002, S. 456-464).

Currently, for the treatment of kidney stones with a variety of drugs.

For litaize urate stones use tool that contains (in a single dose), g:">subcarbonate magnesium 0,2-0,45

pyridoxine hydrochloride 0,013-0,03

(SU 789111, a 61 K 31/00, 1980)

For litaize calcium-oxalate stones used tool on the basis of calcium-sodium-hydrogen-citrate (BLEMAIN) (M. Butz, Clinical assessment BLEMAREN-N, 1997).

However, when using these funds to increase their dose can not only stop the destruction of urate stones, but also to promote the formation on their surface oxalate stones.

Now for litaize urinary stones the most promising is the use of funds on the basis of diphosphonic acids, which can regulate the metabolism of calcium at the cellular level, have low toxicity and determination of actions due to their large chemisorbing means to the main inorganic component of the body - calcium hydroxyapatite.

The greatest interest represents 1 oksietilidendifosfonovaya acid (HEDP), a synthetic analogue of the natural regulator of calcium - pyrophosphate, resistant to chemical and enzymatic degradation in the conditions of the body and has no side effects due to rapid excretion through the kidneys.

Based on exhibiton used in the form of a solution of the following composition, wt.%:

monogalia salt 1 oxoethylidene-

phosphonic acid 17-25

caustic soda 3,5-4,0

purified water rest

(SU 1741801 A1, a 61 K 31/00, 1992).

The drug belongs to the group of chelating agents, provides suppression of crystal formation, growth and aggregation of crystals of oxalate and phosphates of calcium in the urinary tract. Prevents the formation of concrements in the renal pelvis, ureter, urinary bladder and facilitates the passage of stones and sand in uric ways.

The disadvantages of this drug are rapid alkalization of urine, as well as lack of effectiveness of the action.

The problem to which the invention is directed, is to develop a highly efficient means for litaize urinary stones, and how to obtain it. The technical result, which directed the group claimed inventions is to improve litaize without significant side effects due to the possibility of regulating the pH of urine.

The essence of the claimed means for litaize urinary stones based califona is that it additionally contains galangal in a mass ratio of 2:1.

LASS="ptx2">Galangal - erect cinquefoil is a perennial herbaceous plant (D. A. Muraviev. Pharmacognosy. - M.: Medicine, 1978, S. 621-622).

In the roots of tormentil contains 15-30% tannins with a predominance of condensed tannins. These substances are represented mainly by the polymer catechins (flavanols-3). They can form a chelate with the ion of CA2+the group of catechin or leucocyanidins (flavandiols-3,4).

Tannins, in addition to calcium ions can bind with proteins, reducing the absorption of calcium from the intestine into the blood.

The bloodroot is free ellagic acid, which can form complexes with calcium ions. There is also Hinowa acid, which can interact with the organic matrix of the stone.

In the interaction of califona (potassium-sodium salt of HEDP) with ions of CA2+forms a soluble complex with calcium.

Ions of Na+and K+also into solution, forming a strong alkali (NaOH and KOH). When adding a solution of Kalgan, where the active component is ellagic acid, the reaction occurs neutralization.

The hydrogen in the ellagic acid will be replaced by ions of Na+and+.

Thus the attachment of its high complexing ability. It is possible prolonged use of califona without complications.

The present invention is illustrated by the following examples.

20% solution of califona (dosage form) were diluted with water to 2% solution.

1% solution of Kalgan mixed with 2% solution of califona in the ratio of 1:1, which corresponds to the mass ratio of galangal : xidian =1 : 2.

The experiment is carried out in vitro in the urine with an initial pH of 5.5.

In chemical beaker placed in pre-weighed urinary stone, pour 50 ml of urine and add 1 tablespoon of 2%-aqueous solution of califona (0.3 g)+1 tablespoon 1%-aqueous solution of galangal (0.15 g).

During litaize monitor the change in pH of urine and weight of the stone. Was studied 56 of urinary stones.

The results of the research based weight loss at different pH values are presented in the table.

As follows from the data presented in the table, the ratio of xidian : Kalgan = 2 : 1 is optimal. Introduction Kalgan in larger quantities can cause constipation because Kalgan comprises 15-30% of tannins, the introduction of galangal in fewer leads to rapid alkalization of the urine to a pH of 7.3 and 7.5, and starts WIP, nausea prevents the introduction of Kalgan.

Xidian you can apply no more than 14 days. If crystalluria and the presence of concretions in the kidneys spend 5-6 courses with three-week breaks in 1-2 years. The use of califona more than two weeks to sustainable causes alkaline urine (pH>7.5), which can cause bacteria and cause various urological diseases.

Introduction Kalgan allows you to monitor urine pH (pH of about 6.5-6.8) and improves litaize. Without reducing the high complexing ability of califona, galangal affects organic component of the stone, making it more fragile.

The claimed method can be applied prior to sessions shock wave lithotripsy, the number of sessions can be reduced (for stones larger sizes).

1. Means for litaize urinary stones based drug Califon, characterized in that it additionally contains galangal mass ratio of xidian: Kalgan = 2:1.

2. The method of obtaining funds for litaize urinary stones under item 1, which consists in mixing a 2%-aqueous solution of califona with 1% solution of galangal in a 1:1 ratio.

 

Same patents:

The invention relates to pharmaceutical industry and relates to creating funds on the basis of plants with diuretic activity and method of its production
The invention relates to medicine, namely, neurology, and can be used in the treatment of patients with acute urinary retention in the early period of spinal stroke
The invention relates to medicine, in particular to urology and endocrinology

Drug // 2234331
The invention relates to the field of pharmaceuticals, namely, to medicines, and can be used to adjust the chemical composition of food, for example, metabolic disorders in patients with chronic renal failure

The invention relates to new compounds of formula I and Ia in all their stereoisomeric forms or their mixtures in all ratios, and their pharmaceutically acceptable salts, which has antagonistic activity against vitronectin receptor
The invention relates to medicine, more specifically to urology and may find application in the treatment of dysuria
The invention relates to medicine, in particular to urology, and can be used for the treatment of nephrolithiasis

The invention relates to medicine, infectious diseases, helminthology and can be used for the treatment of opisthorchiasis

The invention relates to medicine, gynecology, and can be used to prevent the development of adhesions in the pelvis and disorders of ovarian-menstrual cycle in women undergoing endoscopic surgery on the ovaries using electrocautery
The invention relates to the food and pharmaceutical industry and relates to a method of obtaining a product containing biologically active substances from plant material by extraction with liquefied gas

The invention relates to biotechnology and can be used in medical, cosmetic and food industry

The invention relates to a method for producing a medicinal substance - allapinina of plant materials used as antiarrhythmic agent, with the aim of increasing output allapinina and simplify the technological process

The invention relates to medicine, in particular to the pharmaceutical industry, and is intended for the prevention of exacerbations of chronic and acute inflammatory diseases of the respiratory system

The invention relates to the pharmaceutical industry and is used for the prevention and adjuvant therapy of inflammatory skin diseases, skin itching, to improve the overall condition of the skin
The invention relates to pharmaceutical industry, is used for the prevention and treatment of colds, diseases of the cardiovascular system and bone injuries
The invention relates to the field of pharmaceutical industry and relates to a medicinal product for the treatment of diseases of musculoskeletal system

The invention relates to the production of natural extracts and can be used in food and other industries
The invention relates to the field of medicine and relates to means for the prevention and treatment of caries, hyperesthesia, remineralization of hard tissues of teeth
Up!